# Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

> **NCT00445692** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- DS Stage I Plasma Cell Myeloma
- DS Stage II Plasma Cell Myeloma
- DS Stage III Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Clarithromycin
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00445692
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01-10
- **Primary completion:** 2017-04-24
- **Final completion:** 2017-04-24
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445692, "Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00445692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*